LAIR-1 levels were variable across AML patients, with granulocyte-macrophage progenitor–like (GMP-like) and CD34+CD38+ subsets expressing the highest overall levels of LAIR-1 receptor (Figure 1D). This evidence concerns the gene CD34 and acute myeloid leukemia.